iVeena Delivery Systems, based in Salt Lake City, Utah, operates in the ophthalmology sector, focusing on developing innovative treatments for eye conditions such as keratoconus, progressive myopia, and cystoid macular edema. The company targets patients and physicians seeking advanced, minimally invasive solutions for these unmet medical needs. iVeena's business model revolves around two core platform technologies: the topical delivery of copper for corneal conditions and drug delivery from the lens capsule for cataract-related issues. These technologies are designed to provide impactful and less invasive treatment options, enhancing patient outcomes and simplifying the therapeutic process for healthcare providers. iVeena generates revenue through the development and commercialization of these proprietary technologies, potentially partnering with larger pharmaceutical companies for distribution and further development. The company is supported by a robust advisory board comprising industry experts and seasoned professionals in the field of ophthalmology.

Keywords: ophthalmology, keratoconus, progressive myopia, cystoid macular edema, cornea, cataract, copper delivery, lens capsule, minimally invasive, patient outcomes.